Navigation Links
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Date:5/18/2009

expanded in August 2006 to include the joint development and commercialization of a fixed-dose combination of indacaterol and mometasone furoate. The collaboration has completed the mometasone furoate/formoterol combination's phase II (asthma, COPD) and phase III (asthma) development, while phase III (COPD) continues. Meanwhile, the indacaterol/mometasone combination is in phase II development (asthma, COPD).

Combination products containing inhaled corticosteroids and long-acting beta2-agonists are the largest segment of the worldwide market for asthma and COPD medications, in terms of dollar sales.(1)

Under the revised agreements, Schering-Plough will assume the remaining development and commercialization costs of the mometasone furoate/formoterol fixed-combination product which will utilize a meter-dose inhaler device while Novartis will assume the remaining development and future commercialization costs of the indacaterol/mometasone furoate combination including the Schering-Plough TWISTHALER(R) multi-dose dry powder inhaler device. There will be a royalty sharing arrangement based on sales. Schering-Plough will recognize sales worldwide for mometasone furoate/formoterol upon commercialization. In addition, Schering-Plough will receive royalties and other compensation for Novartis' use of the Schering-Plough TWISTHALER device.

This transaction is subject to approval in accordance with the Hart-Scott-Rodino Act.

Background on Schering-Plough and Novartis respiratory collaborations

In October 2002, Schering-Plough and Novartis announced an agreement giving Schering-Plough exclusive U.S. distribution and marketing rights to Novartis' FORADIL AEROLIZER(R). In April 2003, the two companies announced an agreement for the joint worldwide development and marketing of a new combination treatment of the active ingredients in Schering-Plough's ASMANEX and Novartis' FORADIL.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
2. Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings
3. Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
4. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
7. Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
8. Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
9. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
10. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
11. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
(Date:9/29/2014)... , Sept. 29, 2014 Research ... "Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph Market ... & Region - Global Trends & Forecast to 2013 ... A process analyzer is a process analytical instrument ... real-time. It has redefined the way by which companies ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, is pleased to ... Chairman of the Board of Directors of SQI, replacing ... serve as a Director on the Board and will ... "We are very pleased to have Mr. Winkley ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies,in the ... that the Company,received approval from the PRC ... commence clinical trial of its new Human ...
... Cytotoxic ... Compound Market, ... development organization supporting the,pharmaceutical industry -- today announced the opening ... The 18,000 sq. ft. facility includes newly constructed analytical and,formulation ...
... (Nasdaq: SGMO ) announced today that Edward Lanphier,Sangamo,s ... progress of,Sangamo,s ZFP Therapeutic development programs and an overview ... Tuesday, September 23,2008, at the 2008 UBS Global Life ... will be webcast live and may be accessed via ...
Cached Biology Technology:China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility 2Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 2
(Date:9/29/2014)... . Montreal, ... expectant mother was deprived of electricity during Quebec,s Ice ... a new study finds., Scientists from the Douglas Mental ... distinctive ,signature, in the DNA of children born in ... months after the event, researchers recruited women who had ...
(Date:9/29/2014)... Sclerosis (MS) were able to safely tolerate treatment with ... study published today in the journal Multiple Sclerosis ... first of its kind, was conducted by researchers at ... and collaborators at several other institutions. , While ... in the data also suggested that a preparation of ...
(Date:9/27/2014)... The first direct comparison of treating non-squamous lung ... to cisplatin has shown that the two combinations ... with more frequent adverse events. , At the ... from Chonnam National University Medical School, South Korea, ... trial that included 149 patients with non-squamous non-small ...
Breaking Biology News(10 mins):Cells from placentas safe for patients with multiple sclerosis 2Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca 2
... molecule made by the human body that triggers the immune ... to new research published today in Nature Medicine . ... that if scientists could block this signal, it may be ... is the most common autoimmune disease, affecting around 1 in ...
... canopies bear little resemblance to their seedlings, many described ... "Seedlings of Barro Colorado Island and the Neotropics," published ... Garwood, professor of plant biology at the University of ... describing seedling stages of tropical plants 25 years ago ...
... Lieberman (I-CT) and John Cornyn (R-TX) today introduced the ... ensure free, timely, online access to the published results ... proposed bill is welcomed by the Alliance for Taxpayer ... others formed to support open public access to publicly ...
Cached Biology News:New trigger for chronic inflammation in rheumatoid arthritis discovered 2New guide to tropical seedlings: Essential to climate change research 2Taxpayer Alliance applauds bill to broaden access to federal research results 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
...
... Gel loading buffer is especially formulated for ... nucleic acids. The gel loading solution contains ... to add density and facilitate sample loading. ... that require divalent cations and SDS has ...
Biology Products: